George Dimitrov, M.D., joined Kura as Vice President, Pharmacovigilance and Drug Safety in May 2020, bringing more than 21 years of pharmaceutical industry experience in drug safety and clinical development. Dr. Dimitrov provides strategic safety expertise to ensure the overall integrity of safety medical assessments for Kura’s therapeutics. Prior to Kura, he held multiple positions at EMD Serono, including as Executive Medical Director and Therapeutic Area Head, Immuno-Oncology most recently. While at EMD Serono, Dr. Dimitrov led and mentored a group of physicians responsible for the safety of immuno-oncology programs. He has served in many additional drug safety and pharmacovigilance positions at other pharmaceutical companies, including InterMune, Astex Pharmaceuticals, Spectrum Pharmaceuticals, Amgen, Idec, and Elan Pharmaceuticals. Throughout his career, Dr. Dimitrov has contributed to the development of multiple approved drugs, including Zevalin, Prialt, Tisabri, Nplate and Avelumab. Before entering the industry, Dr. Dimitrov spent 10 years as a practicing physician hematologist and assistant professor of hematology. He received his M.D. degree and board certifications in internal medicine and hematology from the Sofia University of Medicine in Bulgaria.